The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator, was being investigated in the REZOLVE-AD ...

Nektar Therapeutics said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares up by nearly 140%. In the 393-patient global ...